Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 9, 2024Journal of Pharmacy Practice

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor-Related Euglycemic Diabetic Ketoacidosis: A Case Series

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMackenzi MeierBABenedicta AnsongDADolapo Awobusuyi

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Meier et al. (2024) studied this question.

synapsesocial.com/papers/68e5cdb7b6db643587563e67https://doi.org/10.1177/08971900241273169
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study2022 · 92 citations
  2. 2Metformin-associated lactic acidosis: Current perspectives on causes and risk2015 · 664 citations
  3. 3Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents2017 · 89 citations
  4. 4Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program2015 · 326 citations
  5. 5Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy2021 · 105 citations